Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.
The U.S. FDA approved a bone-building drug from Pfenex Inc. to treat osteoporosis in certain patients at high risk for fractures, marking the company’s first commercial product.
AstraZeneca presented results for a late-stage clinical trial of Lynparza against prostate cancer, which the company hopes could lead to wider regulatory approval for more forms of the disease.
Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.
GlaxoSmithKline and AstraZeneca both reported late-stage clinical trial results that will likely make their competing medicines available to a wider group of ovarian cancer patients, possibly helping GSK catch the company’s rival in a highly contested drug class.
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill approved by U.S. authorities that caters for patients with an aversion to needles.
Denmark’s Lundbeck agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.
Biogen Inc. and Eisai Co. Ltd. are abandoning two late-stage trials for their Alzheimer’s treatment elenbecestat in a widely anticipated move that comes months after the companies scrapped studies of aducanumab for the memory-robbing disease.
Tocagen Inc.’s shares fell nearly 80 percent after the company’s experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition.
Cigna introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers.